This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Gilead Sciences, Inc.. Active years: 2024.
Company Filing History:
Years Active: 2024
Title: Sarah E Wortman: Innovator in Pharmaceutical Chemistry
Introduction
Sarah E Wortman is a prominent inventor based in Sacramento, CA. She has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of MCL-1 inhibitors. Her work focuses on creating innovative solutions that can lead to advancements in therapeutic applications.
Latest Patents
Wortman holds a patent for "Salts and polymorphs of certain MCL-1 inhibitors." This patent relates to the salts and crystalline forms of specific 3',4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene] derivatives. The disclosure also covers pharmaceutical formulations and therapeutic uses of these compounds, as well as methods for preparing such salts and crystalline forms.
Career Highlights
Sarah E Wortman is currently employed at Gilead Sciences, Inc., where she continues to push the boundaries of pharmaceutical research. Her innovative work has the potential to impact the treatment of various diseases, showcasing her dedication to improving healthcare through scientific advancements.
Collaborations
Wortman has collaborated with notable colleagues, including Christopher S Regens and John Enquist, Jr. These partnerships highlight the collaborative nature of research and development in the pharmaceutical industry.
Conclusion
Sarah E Wortman is a trailblazer in the field of pharmaceutical chemistry, with a focus on MCL-1 inhibitors. Her contributions through patents and collaborations reflect her commitment to advancing medical science.